Efficacy of statins to reduce the incidence of pacemaker induced cardiomyopathy – An open label randomized controlled trial

The primary purpose of this protocol is to assess the effectiveness of statins in decreasing the incidence of pacemaker-induced cardiomyopathy (PICMP) among patients receiving permanent pacemakers. Right ventricular pacing can lead to left ventricular dysfunction over time, resulting in PICMP, with an incidence reported between 5% to 30% of cases. This study hypothesizes that daily administration of 40 mg of atorvastatin will mitigate PICMP incidence by stabilizing cardiac function over a 1-year period. Should the results prove favorable, this intervention could support the routine use of statins as a preventive measure in pacemaker patients, ultimately aiming to improve their long-term cardiac outcomes and reduce progression to heart failure.